The NCI Cancer Prevention and Control Clinical Trials Grant Program provides R01 funding for investigator-initiated clinical trials designed to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, supportive care, and survivorship. Projects should have the potential to advance evidence-based clinical practice or public health.
The program supports Phase 0 through Phase IV clinical trials within the research interests of the NCI Division of Cancer Prevention and Division of Cancer Control and Population Sciences. It does not support trials evaluating cancer diagnosis or the efficacy of oncologic treatments in cancer patients; early-phase therapeutic and diagnostic cancer trials are covered through the companion PAR-25-081 opportunity.
Eligibility Criteria:
- Public and private institutions of higher education may apply.
- Eligible nonprofit organizations, including those with or without 501(c)(3) status, may apply.
- Eligible state, local, tribal, federal, community-based, and regional organizations may apply.
- Foreign/non-U.S. organizations are eligible to apply.
- Non-U.S. components of U.S. organizations and foreign components are also permitted.
- Multiple-PD/PI applications are permitted.
- Cost sharing or matching is not required.
Funding Details:
- Funding mechanism: R01 Research Project Grant.
- Maximum project period: 5 years.
- Applicants requesting $500,000 or more in direct costs in any single year, excluding consortium F&A, must contact the appropriate NCI scientific/research contact at least 8 weeks before submission and comply with NIH policy for large-budget applications.
Deadline:
For the remaining 2026 cycle:
- New applications: October 5, 2026
- Renewal, resubmission, and revision applications: November 5, 2026
- Deadline time: 5:00 PM local time of the applicant organization
- Scientific merit review: March 2027
- Advisory Council review: May 2027
- Earliest project start: July 2027
- NOFO expiration: January 8, 2027.
- Current status: Open
Further Information:
- Official program information: Visit the Simpler.Grants.gov PAR-25-167 opportunity page for the current status, eligibility information, application documents, and funding details.
- Full NCI funding announcement: Read the official PAR-25-167 NOFO for complete scientific scope, clinical trial requirements, review criteria, and submission instructions.
- Application submission: Applications may be prepared through NIH ASSIST, an institutional system-to-system solution, or Grants.gov Workspace, with application status tracked through eRA Commons.
- Companion clinical trial opportunity: Investigators proposing Phase 0–II cancer treatment or diagnostic intervention trials should review the NCI PAR-25-081 Early Phase Cancer Clinical Trials program instead.
- Program contacts: Applicants should consult Section VII – Agency Contacts of the official PAR-25-167 announcement to identify the appropriate NCI scientific contact for prevention, cancer control, healthcare delivery, survivorship, or other proposed research areas.